
Sponsors

University of Minnesota

College of Veterinary Medicine

College of Food, Agricultural and Natural Resource Sciences

Extension Service

Swine Center

Thank you to **IDEXX Laboratories** for their financial support to reproduce the conference proceeding book.

Production Leader

Steven Claas

Production Assistant

Steven Claas

Janice Storebo

Sarah Summerbell

Layout and CD-ROM

David Brown

Tina Smith

Logo Design

Ruth Cronje, and Jan Swanson;

based on the original design by Dr. Robert Dunlop

The University of Minnesota is committed to the policy that all persons shall have equal access to its programs, facilities, and employment without regard to race, color, creed, religion, national origin, sex, age, marital status, disability, public assistance status, or sexual orientation.

Development of a quantification method to specific Anti-ORF2 antibody using a blocking ELISA

S. Guilloussou^{1,2}, E. Lebon³, L. Mieli³, M. Bonnard⁴, D. Thomson¹

¹Kansas State University, College of Veterinary Medicine, Department of Clinical Science, Manhattan, KS, USA; ²Synbiotics Corporation, Manhattan, KS, USA; ³Laboratoire de Développement et d'Analyses 22, Zoopole, Ploufragan, France; ⁴Synbiotics Europe, Lyon, France

Introduction and Objectives

The objective of the study was to develop a quantitative serum antibody test for PCV2 in swine with a commercially available test (SERELISA[®] PCV2 Ab Mono Blocking, Synbiotics Corporation). This test is based on a blocking Enzyme-Linked ImmunoSorbent Assay (ELISA) which allows specific detection of anti-ORF2 antibodies against PCV2.

Material and methods

Results of the test are expressed as sample to negative control optical density (OD) ratio corrected by the positive control OD and referred as s/n ratio. The linear range of the bELISA was determined by conducting the assay with the s/n ratio of a positive reference sample at different dilutions starting at 1:10 (increasing by 2 and 10 dilution factors) and 1:50 (increasing by 10 dilution factors) in order to recreate a panel of samples ranging from strong positive to weak positive.

After graphical analysis, determination coefficients (r^2) were calculated for different models with variable transformations for s/n ratio and the dilution of titer. Transformations were analyzed for the relationship between titer (T), 1/T, and log T and s/n ratio (sn), 1/sn, log sn and logit sn.

This model was determined within certain limits of dilution titers. Therefore to achieve a valid quantification method from negative to highly positive samples, different dilutions were selected and interpolation was calculated between results obtained from different wells.

Determinations of coefficients and regression equations were calculated using R version 2.4.1.. ANOVA for the robustness study was performed using the same statistical computing software

Results

Linear s/n ratio values ranging from 0.11 to 0.93 were determined using the reference PCV2 positive serum sample at different dilutions.

Comparing seven different regression models correlating different s/n ratio and titer functions, the best model was achieved utilizing the Log of titer and the logit of s/n ratio. This model was

linear with an r^2 of 0.988, a slope of $\beta = -0.703$ and an intersection of $\alpha = 2.652$.

This linear model covered at least a range of a log (base 10) of titer. In order to have a quantitative method valid for serum ranging from negative status to high positive titer, an interpolation using different wells is needed. Inside the linear range, titers range from 100 to 1000 for s/n ratio respectively ranging from 0.895 to 0.242. An arbitrary decision was made to apply this results to the 1/1000 final dilution in the well. Derived from this decision, interpolation was calculated for the two next dilutions of 1:100 and 1:10000. A correcting factor (multiply by 10 or divide by 10) was applied to each of the titer results obtained within these wells and therefore linearity is respected between the three dilution wells. The final model was not limited on the lower bound of the 1:100 well and an arbitrary limit was fixed on the upper bound of the 1:10000 well. This limit corresponds to the very limit of linearity of the regression model ($s/n = 0.107$). Titers obtained are expressed in ELISA units (EU).

Discussion and Conclusions

This model provides a quantitative method for specific detection of anti-ORF2 antibodies against PCV2. The linearity and the robustness have been proven to be effective using three wells in a blocking ELISA. This innovative method provides a quantitative method for a blocking PCV2 ELISA and therefore allows the detection of a specific antibody subpopulation. This method is independent of the seroneutralizing properties of the targeted antibody subpopulation and therefore a nice alternative to Seroneutralizing Tests.

This standardized quantitative test is a tool that will lead to a breakthrough in the understanding of the PCVD epidemiology and be utilized to assess PCV2 control measures such as vaccination.

Acknowledgements

The authors would like to thank MERIAL SAS, France, for providing financial support as well as samples used in this study and especially Dr C. Charreyre and Dr F. Joisel who were the corresponding persons.